Actually, the placebo GBM patient S02-22-1 with no IDH and with methylation lived a little over 5 years at 61.2 months.
It’s obvious that DCVax improves the outcome for GBM methylated. And with recurrence, and they can make a new vaccine with the returning tumor and perhaps we can ultimately turn GBM into a survivable disease.
And in the meantime, the mOS for the DCVax-L with poly ICLC was 28.6 months… which is an improvement over the 19 months shown in the P3 trial. And out of all five in that arm, there was only one methylated patient (living over 52 months), meaning, then, that the remaining four patients who all lived over 24.5 months and higher (the median being 28.6) were unmethylated.
Think on that for a moment. They’ve (UCLA) have created a treatment pathway for unmethylated GBM patients where ALL of them lived at least 24.5 months.
Market Data 
Markets 
AI
